




PROGRAM

Wednesday 31 October

PLENARY				
9:00am– 9:20am	Welcome to AusBiotech 2018 Lorraine Chiroiu , Chief Executive Officer, AusBiotech Video welcome from the Hon Leeanne Enoch , Minister for Environment, Great Barrier Reef, Science and Arts, Qld Government			
9:20am– 10:00am	Keeping the balance in your clinical portfolio - prioritisation versus doing it all Dr Charmaine Gittleson , Chief Medical Officer, CSL Limited			
10:00am– 10:30am	Global life science investing & industry update John Carroll , Editor in Chief, Endpoints			
10:30am– 11:00am	Morning tea & networking with exhibitors in the exhibition hall			
	PLENARY	ROOM 1	ROOM 2	ROOM 3
11:00am– 12:30pm	Precision medicines: maintaining competitiveness in the post-human genome project era <i>This session will discuss the progression of precision medicines onto to the Australian market, implications for the industry & strategies to help Australian companies maintain global competitiveness in the post-human genome project era</i> Chair: Dr Anna Lavelle , Non-Executive Director, Medicines Australia Dr Lisette Pregeli , UQ Post-doctoral Research Fellow, The	The anatomy of a deal <i>This session provides valuable insights from a spectrum of stakeholders with experience in developing complex deals with multinationals in licensing, providing a service or a product</i> Chair: Dr Andrew Kelly , Executive Director, BioPacific Partners Panel: Dr Janette Dixon , Chief Executive Officer/Principal, BioComm Pacific Siddharth Shah , Director - External Innovations, Asia Pacific, Zoetis	<u>Regenerative Medicine Stream</u> A strategic view of the regenerative medicine landscape <i>This session will aim to explore the scientific & regulatory challenges related to progressing cell & gene therapies, highlighting recent scientific, regulatory & launch experience.</i> <i>Launch of MTPConnect 'Regenerative Medicine: Opportunities for Australia' Report</i> Chair: Dr Tim Oldham , Executive Leader, Tijan Ventures	<u>Agriculture & Agtech Stream</u> Gene technologies <i>'GMO' has been a disrupter in the way agriculture is produced but, with the advancement of gene editing technologies such as CRISPR, are GMOs now becoming redundant? Discussing new innovations in gene technologies & nanotech & current & future application in agriculture</i> Chair: Mike Pointon , General Manager Innovation & Development, Nufarm Ltd Prof Peter Waterhouse ,

	<p>University of Queensland Business School Assoc Prof Damian Hine, Strategy, The University of Queensland Business School Prof Karen Hussey, Director – Centre of Policy Futures, The University of Queensland Dr Rob Grenfell, Health Director, Health & Biosecurity, CSIRO Dr Peter Kambouris, Director, BD&C Health & Biosecurity, CSIRO</p>	<p>Dr Birgit Reitmaier, Head of Access to Innovation APAC, Merck</p>	<p>Prof Ian Alexander, Head, Gene Therapy Research Unit, Children’s Medical Research Institute Prof Rajiv Khanna, Senior Scientist, QIMR Berghofer Dr Tim Farries, Director of Regulatory Affairs for Cell & Gene Therapy Products, ERA Consulting UK Lauren Carey, Oncology General Manager, Novartis Australia</p> 	<p>Professor of Molecular Genetics, Science & Engineering Faculty, Earth, Environmental & Biological Sciences, Bioscience, Queensland University of Technology Prof Neena Mitter, Director, Centre for Horticultural Science, QAAFI, The University of Queensland Dr Tim Doran, Group Leader, CSIRO Health & Biosecurity</p> 
<p>12:30pm–1:30pm</p>	<p>Lunch & networking with exhibitors in the exhibition hall & AusBiotech Annual General Meeting in Room 1</p>			
	<p>PLENARY</p>		<p>ROOM 2</p>	<p>ROOM 3</p>
<p>1:30pm-1:40pm</p>	<p>Minster Kate Jones MP Minister for Innovation and Tourism Development, representing the Premier of Queensland</p>			
<p>1:40pm-1:55pm 1:55pm–3:00pm</p>	<p>Johnson & Johnson Innovation Industry Excellence Awards 2018</p> <ul style="list-style-type: none"> - <i>Industry Leadership Award</i> - <i>Australian Company of the Year</i> - <i>Australian Emerging Company of the Year</i> <p>Kathy Connell, Senior Director New Ventures, ANZ, Johnson & Johnson Tony Conaghan, Partner, Thomson Geer Lorraine Chiroiu, Chief Executive Officer, AusBiotech</p>  <p>Big Pharma panel</p>	<p>Regenerative Medicine Stream Australian regenerative medicine translation success stories: <i>Vignettes celebrating successful translation & commercialisation of these novel treatments by Australian companies with a focus on learning. Launch of the Snapshot of the Stem Cell and Regenerative Medicine companies in Australia.</i></p>	<p>Agriculture & Agtech Stream Agtech & big data <i>With big data comes big ideas. The challenge of agtech & science innovation will be to harness the output of the big data revolution. Exploring data capture, prediction & modelling systems for agriculture</i> Chair: Prof Bronwyn Harch, Deputy Vice-Chancellor (Research), The University of Queensland</p>	

Chair: Lorraine Chiroiu, Chief Executive Officer, AusBiotech Ltd
Panel:
Liz Chatwin, Country President, AstraZeneca Aust/NZ
Ben Thorner, Senior Vice President & Head of Business Development & Licensing, Merck Research Laboratories
Kathy Connell, Senior Director New Ventures, ANZ, Johnson & Johnson Innovation
Dr Anand Gautam, Senior Director & Head, External Science & Innovation, Australia, New Zealand & Southeast Asia, Pfizer
Dr Ceri Davies, Senior Research Executive & Global Head, Neuroscience Drug Discovery Unit Head of Research, Takeda Pharmaceutical
Dr Elizabeth Kowaluk, Senior Director, Search & Evaluation, AbbVie

Chair: Silvio Tiziani, Chair Regenerative Medicine Advisory Group, AusBiotech
Prof Alan Trounson, Chief Executive Officer, Cartherics
Craig Newton, Chief Executive Officer, Vivazome
John Martin, Chief Executive Officer, Regeneus
Prof Paul Simmons, Research & New Product Development, Mesoblast

Prof Ben Hayes, Professorial Research Fellow, Centre for Animal Science, QAAFI, The University of Queensland
Prof Guojie Zhang, Associate Director, China National GeneBank, BGI
Dr Nicole Jensen, General Manager, Genetics & Enabling Technologies, GRDC



3:00pm–3:30pm **Afternoon tea & networking with exhibitors in the exhibition hall**

	PLENARY	ROOM 1	ROOM 2	ROOM 3
3:30pm–5:00pm	<p>New gene technology in diagnostics, vaccines & CAR-T therapies Chair: Kylie Sproston, Chief Executive, Bellberry Limited Dr Michelle Fraser, CEO & Managing Director, Reproductive Health Science Limited Dr Tamara Cooper, SIEF STEM+ Research Fellow, Experimental Therapeutics Laboratory, University of South Australia Cancer Research Institute</p>	<p>Your company’s first IND: getting to and through FDA <i>This session is aimed at helping small teams successfully prepare for the process of building & submitting an IND & to establish a productive, collaborative relationship with FDA</i> Chair: Dr Andrea Douglas, Vice President, R&D Strategy & External Affairs, CSL Limited and Director, AusBiotech</p>	<p>Regenerative Medicine Stream Building regenerative medicine industries – international perspectives <i>An account of how different countries are advancing their regenerative medicine activities, in particular the government & regulatory settings to support regenerative medicine advances. Launch of AusBiotech – FIRM Regenerative Medicine Directory</i> Chair: Sue MacLeman, Chair, MTPConnect Ltd</p>	<p>Agriculture & Agtech Stream Food & health <i>Recent achievements and future prospects in development & deregulation of GM foods for improved human health</i> Chair: Dr Allan Green, Innovation Leader, Agriculture & Food, CSIRO Dr James Petrie, Research Scientist, CSIRO Dist Prof James Dale,</p>

Dr Janet Macpherson,
Development Manager, Cell &
Molecular Therapies, Royal Prince
Alfred Hospital

Dr Simone Flight, Senior
Consultant, Clinical Network
Services

Anil Kane, Global Head of
Technical & Scientific Affairs,
Patheon

Daniel Garcia, Senior Director,
Biologics Business Management –
Bioprocess Sciences, Patheon



Korea spotlight:

Dr Bryan Choi, Vice Director,
Strategic Center for Regenerative
Medicine

Japan spotlight:

Dr Yoshitsugu Shitaka, Vice
Chairman, Forum for Innovative
Regenerative Medicine (FIRM)

Israel spotlight:

Dr Shir Mnuchin, VP, Partnerships
Connecting Industry, Academia &
Government, Bioforum Ltd.

Canada spotlight:

Dr Michael May, President &
Chief Executive Officer, CCRM

Belgium spotlight:

Roland Gordon-Beresford,
Chief RA/IP Officer, Novadip
Biosciences



Professor, Institute for Future
Environments, Qld University of
Technology

Prof Mike Gidley, Director,
Centre for Nutrition & Food
Sciences, QAAFI, The University
of Queensland

5:00pm-5:30pm

QAAFI networking event



5:00pm–
7:00pm


AusBiotech 2018 welcome reception in the exhibition hall



Thursday 1 November

PLENARY



9:00am– 9:35am	Millis Oration Chair: Dr Andrea Douglas , Director, AusBiotech & Vice President, R&D Strategy & External Affairs, CSL Limited <i>The three pillars of WEHI’s activities – science, translation & entrepreneurship</i> Prof Doug Hilton , Institute Director, Division Head of Molecular Medicine, Walter & Eliza Hall Institute		
9:35am – 9:45am	Erica Kneipp , Assist Secretary, Australian Government Dept of Health Minister Greg Hunt , Federal Member for Flinders & Minister for Health (video presentation)		
9:45am– 10:30am	PLENARY	ROOM 1	ROOM 2
	Immunology/Oncology – recent advances <i>Now one of the major approaches in the treatment of cancer & autoimmune diseases. Remarkable clinical results with GM cellular therapies (CAR-T) & antibodies against immune checkpoints (CTLA-4, PD-1), have led to successful regulatory approval. The next phase of clinical development will include combination immunotherapies consisting of both cellular & antibody therapeutics. The panel will discuss the latest advances & how novel immunotherapeutic products can be progressed through developmental models & implemented in clinical setting. Launch of the BioExchange platform.</i> Chair: Prof Rajiv Khanna , Senior Scientist, QIMR Berghofer Panel: Dr Michael Rosenzweig , Executive Director, Tumor Immunotherapy, Merck Dr Goslik Schepers , Investment Manager, Brandon Capital Partners Dr Daniel Baker , Vice President, Janssen R&D Dr Anand Gautam , Senior Director & Head, External Science & Innovation, Australia, New Zealand & Southeast Asia, Pfizer	<u>Early stage investment</u> Video welcome from the Hon Leeanne Enoch , Minister for Environment, Great Barrier Reef, Science and Arts, Qld Government Oncology & stem cells presentations Chair: Glenn Cross , AusEvents Business Development Manager, AusBiotech Precision epigenetics: silencing SMCHD1 to treat Prader-Willi Syndrome (PWS) - Walter & Eliza Hall Institute Novel Therapeutics for Parainfluenza - Institute for Glycomics, Griffith University Cell therapy for the treatment of peripheral artery disease– UniQuest, The University of Qld 	Gender diversity in Australian biotech <i>#metoo - A closer look at women in leadership positions, exploring how Australia measures up in terms of women in senior roles, questioning the progress & issues facing women in life sciences. Launch of AusBiotech’s Diversity & Inclusion statement</i> Chair: Sue Charles , Managing Partner, Instinctif Partners Panel: Stuart Roberts , Senior Analyst, NDF Research Samantha Cobb , Chief Executive Officer, AdAlta Dr Krystal Evans , Chief Executive Officer, BioMelbourne Network John Carroll , Editor in Chief, Endpoints Diana Sternfeld , Partner, Fieldfisher



10.30am-11.00am Morning tea & networking with exhibitors in the exhibition hall

	PLENARY	ROOM 1	ROOM 2	ROOM 3
11:00am-12:30pm	<p>Commercialising medicinal cannabis in Australia’s evolving regulatory environment <i>Medical cannabis is legalised in many countries & approved in Australia in late 2016. A number of medical conditions can be treated with cannabis extracts including chronic pain & chemotherapy nausea. There is patient confusion & frustration as the first companies navigate the complex regulatory environment & gain medical acceptance through doctor education. This session will outline the opportunity & progress in getting quality medical cannabis to Australian patients</i></p> <p>Chair: Elaine Darby, Chief Executive Officer, AusCann Prof Cameron Scadding, Executive Chairman, Source Certain International Emily Rigby, Director of Research Programs, Australian Institute for Medical Cannabis</p>	<p>Early stage investment CNS, pain & vaccines presentations Chair: Glenn Cross, AusEvents Business Development Manager, AusBiotech</p> <p>Small molecule therapeutics targeting neuroinflammation in Alzheimer’s disease- QEDDI, UniQuest A novel approach for the treatment of painful diabetic neuropathy – UniQuest, The University of Qld Novel ion channel blockers for the treatment of pain - Vast Bioscience Pty Ltd DNA Vaccine for Hepatitis C and HIV - University of Adelaide Novel Constructs for Flavivirus Vaccines – UniQuest, The University of Qld Molecular Clamp vaccine platform for RSV and influenza – UniQuest, The University of Qld The development of a hyperstable influenza vaccine- James Cook University</p>	<p>From Bench to Bedside Innovation in Drug Development <i>Drug development is getting more challenging, with longer time-to-market, rising costs, and a high rate of failure. New innovations are needed to improve currently entrenched R&D processes. This session will aim to examine drug development today, exploring and identifying innovations that can improve efficiency, productivity, and success of drug development. It will also focus on highlighting a few GPCR drug discovery innovations across a number of therapeutic areas, with the GPCR field having over 80% of targets still to be effectively exploited despite significant market size</i></p> <p>Chair: Dr Angela Qu, Senior Director, Translational Medicine, PAREXEL International</p>	<p>Clinical Trials Stream Harness the power of data for smarter drug development <i>Today, clinical trials are accommodating an incredible variety of data & content from various sources – from traditional clinical data, to high-resolution images, operational data & much more. As clinical trials become more complex, the biggest challenge for stakeholders is to reduce study risk, meet complex regulatory requirements, & reduce the life cycle of the clinical development without compromising the patient’s experience</i></p> <p>Chair: Eunho Shin, Head of Solution Consultant in APAC, Medidata Mark Maclean, Head Clinical Data Management, NHMRC Clinical Trial Centre, University of Sydney</p>



Matt Spitzer, Program Coordinator, Oncology Clinical Trials, Mater Research




Samantha Cobb, Chief Executive Officer, AdAlta
Assoc Prof Kevin Pflieger, Chief Scientific Adviser, Dimerix Ltd
Dr Chris Langmead, Head, Servier Drug Discovery Program, Monash Institute of Pharmaceutical Services





Dr Anthony Good, Vice President, Clinical Research, Imugene
Dr Thomas Polasek, Medical Director, Certara



12:30pm-1:30pm Lunch & networking with exhibitors in the exhibition hall

	PLENARY	ROOM 1	ROOM 2	ROOM 3
1:30pm-3:00pm	<p>Accelerating the path from bench to biotech: focusing on entrepreneurship to drive innovation <i>The effect of building entrepreneurial capability in academic researchers has on transforming the innovation environment with a change in rate of research translation impact</i> Chair: Dougal Edwards, Chief Executive Officer, Bright Arena Panel: Prof Darren Kelly, Chief Executive Officer & Managing Director, Occurx</p>	<p>Early stage investment Oncology presentations Chair: Glenn Cross, AusEvents Business Development Manager, AusBiotech Bi-specific antibodies for cancer immunotherapy- QIMR Berghofer MRI G9a inhibitors for the treatment of breast cancer- QIMR Berghofer MRI Dynamine inhibition to enhance immune-oncology monoclonal antibody efficacy – UniQuest, The University of Qld Immune Checkpoint inhibitors - James Cook University</p>	<p>Digital Health: regulation & new technologies <i>A discussion of the rapid growth of new technologies in health care and approaches to their regulation</i> Chair: Kim O’Connell, Partner, King & Wood Mallesons Panel: Anna Feros, Special Counsel, King & Wood Mallesons Dr Mike Skalsky, Managing Director, Sci2Rx Pty Ltd Brent Maxwell, Amazon Web Services Bronwyn Le Grice, Managing Director, ANDHealth Ltd</p>	<p>Clinical Trials Stream Keys to winning clinical trial tenders in Australia <i>Discussing how to attract sponsors from a Central Lab perspective, the importance of strategic partnerships & attracting sponsors from a CRO perspective & presenting on facing the issue of our global location & turning it into a positive through planning (lane validation, packaging, transit times, infrastructure, population etc)</i> Chair: Dr Megan Robertson, Director of Research, St Vincent’s Hospital</p>

	<p>Dr Jerad Ford, Manager, CSIRO Futures Dr Kath Giles, Investment Manager, Brandon Capital</p>	<p>First in class ion channel inhibitors for the treatment of cancer - QEDDI, UniQuest MeldX, a novel IVD test for detection of early stage melanoma - Edith Cowan University</p> 		<p>Panel: Brent McPherson, National Business Development Manager, World Courier Paulette Azar-Tannous, Chief Executive Officer, Sonic Clinical Trials Dr Michael Winlo, Chief Executive Officer, Linear</p> 
<p>3:00pm – 3:30pm</p>	<p>Afternoon tea & networking with exhibitors in the exhibition hall</p>			
	<p>PLENARY</p>	<p>ROOM 1</p>	<p>ROOM 2</p>	<p>ROOM 3</p>
<p>3:30pm – 5:00pm</p>	<p>Curing paralysis – what innovations do we need to accelerate delivery of an effective therapy <i>Repairing a paralysed spinal cord has long been considered impossible, but now innovative technologies are making this a reality. This session will highlight the demands & needs of the innovation pathway from patient through to advanced digital solutions</i> Chair: Assoc Prof James St John, Head, Clem Jones Centre for Neurobiology & Stem Cell Research, Griffith University</p>	<p>Early stage investment Inflammation & immunology presentations Chair: Glenn Cross, AusEvents Business Development Manager, AusBiotech Novel complement modulators for the treatment of inflammatory and metabolic diseases – UniQuest The University of Qld IL-22 conjugates for the treatment of NASH – UniQuest, The University of Qld Rethinking CD52: a therapy for autoimmune disease - Walter & Eliza Hall Institute</p>	<p>The anatomy of a clinical trials claim <i>A claim made by a patient suffering serious injury in a clinical trial can have a significant impact on the business sponsoring the trial. We will discuss what happens when a clinical trial insurance policy is called upon to respond to a demand for compensation from an injured trial participant. Hear from three experts, an insurance company, an insurance broking house & a legal firm</i> Chair: Estelle Smith, Life Science Manager, Australia & New Zealand, Chubb Insurance</p>	<p>Clinical Trials Stream Niche (neurological) clinical trial capabilities in Australia <i>How we work with biotechnology companies to deliver their project</i> Chair: Dr Tina Soulis, Chief Executive Officer, Neuroscience Trials Australia Dr Andrew Evans, Director of the Movement Disorders Service, Royal Melbourne Hospital Prof Mark Cook, Chair of Medicine, St. Vincent's Hospital Dr Nick Opie, Chief Technology Officer/Founder, Synchron Inc.</p>

	<p>Perry Cross, Executive President, Perry Cross Spinal Research Foundation</p> <p>Dr Brent McMonagle, ENT Surgeon, Gold Coast University Hospital</p> <p>Assoc Prof James St John, Head, Clem Jones Centre for Neurobiology & Stem Cell Research, Griffith University</p> <p>Genny Kroll-Rosen, Clinical Operations Manager, Making Strides</p> <p>Prof David Lloyd, Chair, Gold Coast Orthopaedics Research & Education Alliance</p> 	<p>Intercepting inflammation with RIPK2 inhibitors - Walter & Eliza Hall Institute</p> <p>Reset and Maintenance, a novel approach to the treatment of autoimmune diseases - Biomedicine Discovery Institute, Monash University</p> <p>HPGD2S inhibitors for asthma and allergic disease- UniQuest, The University of Qld</p> 	<p>Panel:</p> <p>Scott Jordan, Senior Claims Technical Specialist, Chubb Insurance</p> <p>Shane Aitken, Chief Operating Officer, Avatar Insurance Brokers</p> <p>Karen Jones, Partner, Wotton & Kearney</p> 	<p>Dr Rebecca Sheean, Research Coordinator, Fight MND</p>
<p>7:00pm – 11:00pm</p>	<p>Conference dinner at the Grand Chelsea Ballroom at the Mercure Brisbane Hotel</p> 			

Friday 2 November

	PLENARY	ROOM 2
<p>9:00am– 10:00am</p>	<p>Investor session</p> <p>Chair: Lawrence Gozlan, Portfolio Manager, Scientia Capital</p> <p>Panel:</p> <p>James leong, Head of IC – Chairman, Pagoda Investment</p>	<p>Artificial intelligence</p> <p><i>The future of medical imaging and the basis and future of data mining and artificial intelligence</i></p> <p>Chair: Dr Anna Lavelle, Non-Executive Director, Medicines Australia</p>

	<p>Amir Zalcenstein, Investment Manager, Oneventures Glenn Begley, Chief Executive Officer, Biocurate Pty Ltd</p>	<p>Dr Rowan Chapman, Head, Johnson & Johnson Innovation Prof Carolyn Mountford, Chief Executive Officer & Director of Research, Translational Research Institute Dr John Irvine, Chief Scientist for Data Analytics, Draper Laboratory Dr Nic Waddell, Group Leader of Medical Genomics, QIMR Dr David Hansen, Chief Executive Officer & Research Director, CSIRO e-Health Research Program</p>
10:00am–10:30am	<p>Update on Innovation & Science Australia Dr Charlie Day, Chief Executive Officer, Office of Innovation & Science Australia</p>	
10:30am–11:00am	Morning tea & networking with exhibitors in the exhibition hall	
11:00am–12:30pm	<p>Global life sciences outlook: leading in an era of unprecedented change <i>Gain insights on the 2019 outlook for life sciences from pharmaceuticals & biotechnology to diagnostics & digital health with key highlights from geographic, technology, competitive & customer perspectives</i> Chair: Glenn Cross, AusEvents Business Development Manager, AusBiotech Mark Dougan, Consulting Director, Transformational Health, Frost & Sullivan Divya Chadha Manek, Head of Business Development, NIHR Clinical Research Network Dr Rowan Chapman, Head, Johnson & Johnson Innovation</p> <p style="text-align: center;">F R O S T  S U L L I V A N</p>	<p>Creating investor value – recent Australian public company exits Chair: Megan Baldwin, Chief Executive Officer, Opthea Limited Rob Daniels, Chief Executive Officer, Elastagen Dr Tony Keating, CEO, ResApp David Blake, Founder, Bioshares Stuart Roberts, Founder & Senior Analyst, NDF Research</p>
12:30pm–2:30pm	Lunch, closing ceremony & handover to AusBiotech 2019 in the exhibition hall	